Vault-13

Propel Bio Management, LLC

Los Angeles, CA · CIK 1969764 · 13F filing filed 2025-08-13

SEC-registered investment adviser since 2022 · limited liability company

As an employer

$82.4m reported value -4.3% vs Q1 2025
16positions
97.5%in top 10
2 new 5 added 2 reduced 4 sold out vs Q1 2025

This report includes the holdings of 1 other manager that shares the investment decisions:

Shares in two reports are counted once in each security's totals.

Holdings, Q2 2025

The small lines show how much was held over the last 4 quarters (adjusted for stock splits).

#SecurityTickerShares Value% of portfolioChangeShares change
1 PLAINS GP HLDGS L P LTD PARTNR INT A PAGP PAGP 1,272,360 $24.7m30.01% 30.01% UnchangedShares held: Q3 2024 1.3m, Q4 2024 1.3m, Q1 2025 1.3m, Q2 2025 1.3m
2 ACHIEVE LIFE SCIENCES INC COM ACHV ACHV 6,153,091 $13.9m16.88% 16.88% AddedShares held: Q3 2024 2.5m, Q4 2024 2.5m, Q1 2025 2.5m, Q2 2025 6.2m +3.7m +3,699,999 150.8%
3 AKERO THERAPEUTICS INC COM AKRO AKRO 228,884 $12.2m14.82% 14.82% UnchangedShares held: Q3 2024 343.7k, Q4 2024 343.7k, Q1 2025 228.9k, Q2 2025 228.9k
4 PHATHOM PHARMACEUTICALS INC COM PHAT PHAT 922,927 $8.9m10.74% 10.74% ReducedShares held: Q3 2024 869.9k, Q4 2024 989.9k, Q1 2025 1.1m, Q2 2025 922.9k -212.0k -212,000 -18.7%
5 ABEONA THERAPEUTICS INC COM NEW ABEO ABEO 974,022 $5.5m6.71% 6.71% AddedShares held: Q3 2024 624.0k, Q4 2024 624.0k, Q1 2025 624.0k, Q2 2025 974.0k +350.0k +350,000 56.1%
6 APPLIED THERAPEUTICS INC COM APLT APLT 11,285,420 $3.5m4.26% 4.26% UnchangedShares held: Q3 2024 6.6m, Q4 2024 9.6m, Q1 2025 11.3m, Q2 2025 11.3m
7 MILESTONE PHARMACEUTICALS IN COM MIST MIST 1,791,557 $3.5m4.22% 4.22% AddedShares held: Q3 2024 0, Q4 2024 0, Q1 2025 1.5m, Q2 2025 1.8m +340.0k +340,000 23.4%
8 DELCATH SYS INC COM NEW DCTH DCTH 226,052 $3.1m3.73% 3.73% AddedShares held: Q3 2024 0, Q4 2024 17.0k, Q1 2025 177.6k, Q2 2025 226.1k +48.5k +48,452 27.3%
9 TSCAN THERAPEUTICS INC COM TCRX TCRX 2,087,139 $3.0m3.67% 3.67% UnchangedShares held: Q3 2024 2.1m, Q4 2024 2.1m, Q1 2025 2.1m, Q2 2025 2.1m
10 ZEVRA THERAPEUTICS INC COM NEW ZVRA ZVRA 231,874 $2.0m2.48% 2.48% AddedShares held: Q3 2024 179.9k, Q4 2024 179.9k, Q1 2025 179.9k, Q2 2025 231.9k +52.0k +52,000 28.9%
11 CAPRICOR THERAPEUTICS INC COM NEW CAPR CAPR 70,000 $695.1k0.84% 0.84% NewShares held: Q3 2024 0, Q4 2024 0, Q1 2025 0, Q2 2025 70.0k
12 MAAT PHARMA SACA COMM MATPF MATPF 94,181 $452.1k0.55% 0.55% ReducedShares held: Q3 2024 2.4k, Q4 2024 3.2k, Q1 2025 166.4k, Q2 2025 94.2k -72.2k -72,242 -43.4%
13 ATHIRA PHARMA INC COM COM 1,492,792 $450.8k0.55% 0.55% UnchangedShares held: Q3 2024 1.5m, Q4 2024 1.5m, Q1 2025 1.5m, Q2 2025 1.5m
14 EIGER BIOPHARMACEUTICALS INC COM NEW CLDN CLDN 146,381 $423.0k0.51% 0.51% UnchangedShares held: Q3 2024 146.4k, Q4 2024 146.4k, Q1 2025 146.4k, Q2 2025 146.4k
15 WTS - Achieve Life Sci COMM COMM 3,699,999 $13.7k0.02% 0.02% NewShares held: Q3 2024 0, Q4 2024 0, Q1 2025 0, Q2 2025 3.7m
16 CHINOOK THERAPEUTICS XXX COM COM 79,357 $2.5k0.00% 0.00% UnchangedShares held: Q3 2024 79.4k, Q4 2024 79.4k, Q1 2025 79.4k, Q2 2025 79.4k

Sold out since Q1 2025

SecurityTickerShares held beforeValue then
MADRIGAL PHARMACEUTICALS INC MDGL MDGL 30,032 $9.9m30.0k shares
AVIDITY BIOSCIENCES INC RNA RNA 178,500 $5.3m178.5k shares
SYNDAX PHARMACEUTICALS INC SNDX SNDX 183,259 $2.3m183.3k shares
COMPASS THERAPEUTICS INC CMPX CMPX 228,317 $433.8k228.3k shares

Stakes above 5%

Companies where this manager has reported owning more than 5% of a class of shares, on Schedule 13D (may seek influence) or 13G (passive): its latest filing for each, from 19 Dec 2024 on.

CompanyTickerStakeChange ScheduleLast filed
MILESTONE PHARMACEUTICALS IN MIST · 13G · filed 2025-12-23 MIST 9.9%≈ $11.9m new 13G 2025-12-23